REGENXBIO Inc.

RGNX

REGENXBIO Inc.

RGNX

Insider Sentiment (TTM):

Last Purchase:-Last Sale:2026-05-11Shares Purchased (TTM):0Shares Sold (TTM):56,602

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:38,540,622Shares Outstanding:52,428,000Institutional Ownership Pct.:73.51%

Earnings Market Reaction:

Filing Date:2026-08-06Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	36	15	34	59	80	130	58	57	58	113	35	53
Marketable Securities Current	69	135	196	215	244	138	177	199	233	226	241	249
Accounts Receivable Net Current	107	10	26	25	20	18	20	24	23	16	25	28
Prepaid Expense Current	12	12	12	13	11	11	9	11	10	14	15	13
Other Assets Current	12	14	13	19	19	16	14	23	23	27	20	23
Assets Current	236	187	281	332	374	313	278	313	347	395	335	366
Marketable Securities Noncurrent	-	-	11	28	40	5	10	23	37	42	39	63
Accounts Receivable Net Noncurrent	0	0	2	3	2	1	0	0	0	1	1	1
Property Plant And Equipment Net	98	102	105	108	111	114	118	121	124	128	132	136
Operating Lease Right Of Use Asset	44	46	47	49	50	52	54	55	56	58	60	62
Restricted Cash And Cash Equivalents Noncurrent	2	2	2	2	2	2	2	2	2	2	2	2
Other Assets Noncurrent	6	6	5	4	2	3	4	4	3	4	5	5
Assets	387	342	453	525	581	491	466	519	569	629	574	634
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	16	21	21	22	22	19	23	20	16	31	23	22
Contract With Customer Liability Current	10	6	10	13	14	14	0	0	0	0	0	0
Operating Lease Liability Current	7	8	8	9	8	8	8	8	7	7	7	7
Liabilities Current	83	71	118	125	120	107	103	103	98	110	130	127
Contract With Customer Liability Noncurrent	15	23	19	21	24	26	-	-	-	-	-	-
Operating Lease Liability Noncurrent	62	63	65	67	70	72	74	76	78	80	82	84
Other Liabilities Noncurrent	0	1	1	1	1	1	4	4	4	3	6	6
Liabilities	315	321	350	364	367	217	206	218	221	239	262	271
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	1,266	1,238	1,229	1,221	1,211	1,201	1,193	1,183	1,172	1,162	1,021	1,013
Accumulated Other Comprehensive Income Loss Net Of…	-1	-1	-1	-1	-1	-1	-1	-1	-2	-3	-4	-7
Retained Earnings Accumulated Deficit	-1,193	-1,216	-1,126	-1,059	-997	-926	-932	-881	-821	-768	-705	-642
Stockholders Equity	72	21	103	161	214	274	260	301	348	391	312	363
Liabilities And Stockholders Equity	387	342	453	525	581	491	466	519	569	629	574	634
Allowance For Doubtful Accounts Receivable Current	-	-	-	-	-	-	-	-	-	-	5	-
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	100	100	100	100	100	100	100	100	100	100	100	100
Common Stock Shares Issued	54	52	51	51	50	50	50	50	49	49	44	44
Shares Outstanding	54	52	51	51	50	50	50	50	49	49	44	44

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-2.64%	112.65%	55.16%	-	-	-	-	-	-	-	-	-
2025	20.58%	9.66%	2.76%	13.04%	22.15%	64.94%	19.87%	26.77%	23.46%	-11.01%	0.46%	-27.18%
2024	-13.92%	-29.81%	-14.04%	-8.87%	-12.17%	-16.60%	5.20%	-21.42%	-16.44%	-3.97%	58.78%	35.11%
2023	-	-	-	-	-	-	19.87%	9.38%	-22.49%	8.79%	-21.63%	-20.13%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	2.86	2.62	2.38	2.66	3.13	2.93	2.69	3.05	3.53	3.59	2.57	2.87
Quick Ratio	2.71	2.46	2.28	2.56	3.04	2.83	2.61	2.94	3.43	3.47	2.46	2.77
Working Capital	153.54M	115.41M	163.19M	207.40M	254.21M	206.51M	174.81M	210.67M	248.41M	285.24M	204.70M	238.49M
Leverage & Debt
Debt to Equity	4.39	15.22	3.41	2.25	1.72	0.79	0.79	0.72	0.63	0.61	0.84	0.75
Interest Coverage TTM	-3.91	-5.69	-3.58	-3.68	-5.52	-8.17	-18.43	-53.39	-45.99	-43.72	-39.07	-26.71
Debt Ratio	0.81	0.94	0.77	0.69	0.63	0.44	0.44	0.42	0.39	0.38	0.46	0.43
Efficiency & Turnover
Asset Turnover TTM	0.36	0.21	0.37	0.31	0.27	0.28	0.16	0.15	0.14	0.13	0.13	0.13
Days Sales Outstanding TTM	132.79	58.66	50.17	55.38	50.38	39.62	99.13	111.77	90.57	73.00	106.93	111.28
Receivables Turnover TTM	2.75	6.22	7.28	6.59	7.24	9.21	3.68	3.27	4.03	5.00	3.41	3.28
Per Share Metrics
Diluted EPS TTM	-3.71	-5.53	-3.76	-3.44	-3.41	-3.07	-4.59	-4.70	-4.76	-5.69	-6.02	-5.93
Free Cash Flow Per Share TTM	-4.73	-4.51	-2.45	-2.06	-1.76	-1.69	-3.55	-3.64	-3.85	-4.34	-5.22	-5.26
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	-	-	-	-	-	-	59.72%	54.36%	56.78%	56.89%	58.76%	61.00%
Operating Profit Margin TTM	-94.08%	-292.28%	-94.58%	-96.04%	-105.66%	-100.41%	-280.03%	-291.58%	-279.37%	-306.52%	-297.12%	-263.65%
Net Profit Margin TTM	-112.58%	-330.23%	-113.75%	-110.29%	-112.70%	-100.62%	-272.54%	-283.19%	-270.74%	-299.97%	-291.99%	-262.18%
Growth Metrics
Net Revenue Growth (1Y)	12.00%	-43.96%	104.54%	91.30%	74.95%	80.70%	-7.66%	-15.14%	-8.18%	-20.90%	-19.94%	-79.30%
Net Income Growth (1Y)	11.88%	83.91%	-14.63%	-25.50%	-27.17%	-39.38%	-13.81%	-8.34%	-12.07%	-3.75%	-6.00%	-453.82%
EPS Growth (1Y)	9.05%	80.17%	-18.05%	-26.78%	-28.42%	-46.03%	-23.86%	-20.71%	-24.35%	-8.55%	-7.25%	-448.23%
Valuation Metrics
P/E TTM	-3.22	-1.51	-3.83	-2.80	-2.41	-2.33	-1.69	-2.23	-2.46	-3.70	-2.98	-2.78
P/B TTM	8.82	20.84	7.23	3.09	1.98	1.34	1.47	1.77	1.70	2.47	2.52	1.99
P/S TTM	3.63	5.00	4.36	3.09	2.71	2.34	4.59	6.32	6.65	11.11	8.70	7.28
Market Cap	632.78M	439.35M	742.65M	498.80M	422.68M	367.24M	382.70M	532.89M	592.03M	963.59M	785.03M	723.33M
Enterprise Value	596.30M	424.12M	708.19M	440.00M	343.12M	237.13M	325.18M	476.27M	534.27M	850.62M	750.50M	670.29M
Calculated Values
Free Cash Flow TTM	-249.67M	-236.40M	-126.38M	-106.28M	-90.71M	-86.94M	-175.56M	-184.74M	-194.72M	-198.64M	-228.37M	-231.32M
Net Debt	-36.49M	-15.23M	-34.47M	-58.80M	-79.56M	-130.10M	-57.53M	-56.62M	-57.77M	-112.98M	-34.52M	-53.05M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-05-11Sale

Owner: Pakola, Steve

Title: Chief Medical Officer

Shares: 15,309

Price/Share: $11.02

Value: $168,705.18

Shares Owned: 232,617

Relationship: Officer

Ownership: Direct

2026-03-10Sale

Owner: Pakola, Steve

Title: Chief Medical Officer

Shares: 5,124

Price/Share: $10.35

Value: $53,033.40

Shares Owned: 247,926

Relationship: Officer

Ownership: Direct

2025-10-09Sale

Owner: Simpson, Curran

Title: Chief Executive Officer

Shares: 20,811

Price/Share: $12.62

Value: $262,634.82

Shares Owned: 216,162

Relationship: Director,Officer

Ownership: Direct

2025-09-29Sale

Owner: Simpson, Curran

Title: Chief Executive Officer

Shares: 7,624

Price/Share: $10.03

Value: $76,468.72

Shares Owned: 236,973

Relationship: Director,Officer

Ownership: Direct

2025-09-10Sale

Owner: Simpson, Curran

Title: Chief Executive Officer

Shares: 7,734

Price/Share: $10.02

Value: $77,494.68

Shares Owned: 244,597

Relationship: Director,Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-05-11	Pakola, Steve	Officer	Chief Medical Officer	Direct	Sale	15,309	11.02	$168,705.18	232,617	4
2026-03-10	Pakola, Steve	Officer	Chief Medical Officer	Direct	Sale	5,124	10.35	$53,033.40	247,926	4
2025-10-09	Simpson, Curran	Director,Officer	Chief Executive Officer	Direct	Sale	20,811	12.62	$262,634.82	216,162	4
2025-09-29	Simpson, Curran	Director,Officer	Chief Executive Officer	Direct	Sale	7,624	10.03	$76,468.72	236,973	4
2025-09-10	Simpson, Curran	Director,Officer	Chief Executive Officer	Direct	Sale	7,734	10.02	$77,494.68	244,597	4
2025-05-12	Mills, Kenneth T.	Director	-	Direct	Sale	20,602	7.91	$162,961.82	475,103	4
2024-10-01	Karabelas, Argeris N	Director	-	Direct	Sale	10,000	10.11	$101,100.00	11,286	4
2024-09-03	Karabelas, Argeris N	Director	-	Direct	Sale	10,000	11.92	$119,200.00	11,286	4
2024-08-01	Simpson, Curran	Director,Officer	Chief Executive Officer	Direct	Sale	100	15.00	$1,500.00	170,037	4
2024-08-01	Karabelas, Argeris N	Director	-	Direct	Sale	10,100	14.35	$144,935.00	11,286	4
2024-07-29	Karabelas, Argeris N	Director	-	Direct	Sale	11,000	15.05	$165,550.00	11,286	4
2024-07-29	Simpson, Curran	Director,Officer	Chief Executive Officer	Direct	Sale	9,648	15.04	$145,105.92	170,137	4
2024-07-25	Mills, Kenneth T.	Director	-	Direct	Sale	15,369	13.96	$214,551.24	408,035	4
2024-07-17	Mills, Kenneth T.	Director	-	Direct	Sale	2,210	13.77	$30,431.70	408,035	4
2024-07-01	Karabelas, Argeris N	Director	-	Direct	Sale	10,000	11.27	$112,700.00	11,286	4
2024-05-14	Mills, Kenneth T.	Director,Officer	President and CEO	Direct	Sale	15,000	15.81	$237,150.00	408,035	4
2024-04-15	Mills, Kenneth T.	Director,Officer	President and CEO	Direct	Sale	15,000	18.19	$272,850.00	408,035	4
2024-03-14	Mills, Kenneth T.	Director,Officer	President and CEO	Direct	Sale	15,000	21.86	$327,900.00	408,035	4
2024-03-05	Pakola, Steve	Officer	Chief Medical Officer	Direct	Sale	12,878	28.36	$365,220.08	107,192	4
2024-02-14	Mills, Kenneth T.	Director,Officer	President and CEO	Direct	Sale	15,000	16.67	$250,050.00	408,035	4
2024-01-16	Mills, Kenneth T.	Director,Officer	President and CEO	Direct	Sale	45,000	15.18	$683,100.00	408,035	4
2024-01-03	Pakola, Steve	Officer	Chief Medical Officer	Direct	Sale	17,237	17.39	$299,751.43	107,192	4
2023-12-19	Mills, Kenneth T.	Director,Officer	President and CEO	Direct	Sale	45,000	19.69	$886,050.00	355,289	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

73.51%

Inst. Shares: 38,540,622

Shares Outstanding: 52,428,000

2025-12-31

77.78%

Inst. Shares: 40,112,103

Shares Outstanding: 51,573,000

2025-09-30

78.40%

Inst. Shares: 40,524,928

Shares Outstanding: 51,689,000

2025-06-30

79.62%

Inst. Shares: 40,993,230

Shares Outstanding: 51,483,000

2025-03-31

79.22%

Inst. Shares: 40,686,910

Shares Outstanding: 51,362,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	38,540,622	52,428,000	73.51%
2025-12-31	40,112,103	51,573,000	77.78%
2025-09-30	40,524,928	51,689,000	78.40%
2025-06-30	40,993,230	51,483,000	79.62%
2025-03-31	40,686,910	51,362,000	79.22%
2024-12-31	41,271,618	49,509,000	83.36%
2024-09-30	42,584,471	50,800,000	83.83%
2024-06-30	43,090,755	50,601,000	85.16%
2024-03-31	41,748,144	45,733,000	91.29%
2023-12-31	37,539,143	43,734,000	85.84%
2023-09-30	35,791,762	43,945,000	81.45%
2023-06-30	35,804,794	43,531,000	82.25%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

REGENXBIO Inc. (RGNX) — SEC Financial Statements & Analysis

REGENXBIO Inc. (RGNX) is a biological products, (no diagnostic substances) company. REGENXBIO Inc. trades on Nasdaq as: RGNX. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), REGENXBIO Inc. reported a 12.00% year-over-year revenue growth, a Gross Profit Margin of 59.72% (TTM), a Debt-to-Equity ratio of 4.39x, a Price-to-Sales (P/S) ratio of 3.63x (TTM), a Price-to-Book (P/B) ratio of 8.82x (TTM), at a market cap of $632.78M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 12.00%
Gross Profit Margin TTM: 59.72%
Debt To Equity: 4.39x
P/S TTM: 3.63x
P/B TTM: 8.82x
Market Cap: $632.78M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is REGENXBIO Inc. in?

REGENXBIO Inc. (RGNX) operates in the Biological Products, (No Diagnostic Substances) industry.

What is RGNX's market cap?

REGENXBIO Inc. (RGNX) has a market capitalization of $632.78M as of 2026-06-30.

What exchange does RGNX trade on?

REGENXBIO Inc. (RGNX) trades on the Nasdaq.

REGENXBIO Inc.

Financial Statements

Custom Table

Interactive Financial Visualizations

Earnings Market Reaction

Performance and Valuation Metrics

Insider Transactions

Institutional Ownership

REGENXBIO Inc. (RGNX) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Biological Products, (No Diagnostic Substances)

Wall Street's data.
Main Street's price.

REGENXBIO Inc. (RGNX) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Biological Products, (No Diagnostic Substances)

Wall Street's data.Main Street's price.

Wall Street's data.
Main Street's price.